Highlights

  • ValiRx launches a fundraising to raise up to GBP 1.05M through placing and retail offer.
  • Issue price set at 0.25p per share, representing a 45.7% discount to last close.
  • Warrants attached on a one-for-one basis, exercisable at 0.5p per share.

ValiRx PLC (LSE:VAL), a life sciences company focused on early-stage cancer therapeutics and women’s health, announced a fundraising of up to GBP 1.05M (before expenses).

Fundraising Structure and Details

The fundraising includes a firm placing of 112.3M Tranche 1 shares, a conditional placing of 183.7M Tranche 2 shares, a WRAP Retail Offer for up to 120M shares, Director/PDMR subscriptions for 4M shares, and Fee Shares totaling 7.65M.

All new shares are being issued at 0.25 pence per share, representing a 45.7% discount to the previous day’s closing price of 0.46 pence. SP Angel Corporate Finance LLP and Shard Capital acted as placing agents for the transaction.

The WRAP Retail Offer, which allows retail investors to participate on the same terms. The results of the offer and the final fundraising amount are expected on or around 4 November 2025.

Warrants and Broker Arrangements

Each new share subscribed under the placing, subscription, or WRAP Retail Offer will include a Fundraising Warrant on a one-for-one basis, exercisable at 0.5 pence per share—a 100% premium to the issue price. The Fundraising Warrants can be exercised any time within three years from Tranche 2 Admission, subject to shareholder approval at the upcoming General Meeting.

Additionally, the company will issue 19M Broker Warrants to SP Angel, Shard, and Winterflood, exercisable at the issue price per share for three years. The company has also agreed to issue 7.65M Fee Shares with attached Fundraising Warrants in lieu of certain advisory and commission fees.

Management Participation and Use of Proceeds

Company directors and closely associated persons have subscribed for 4M shares and participated in the placing for 36M shares, contributing a total of GBP 0.1M.

According to the company, gross proceeds of approximately GBP 0.75M have been raised from the placing and subscription, with an additional GBP 0.3M potentially raised through the WRAP Retail Offer.

Management Comments

Martin Gouldstone, Non-Executive Chairman, said:

“I am pleased to see the Company successfully close this round during a difficult funding environment, this will enable us to continue to develop important novel therapies in oncology and female health to ultimately benefit patients.”

Mark Eccleston, CEO, stated:

“The Company now operates a lean model building on the restructure implemented earlier in the year and the funds will be used primarily to expand our evaluation pipeline whilst progressing existing SPVs, Cytolytix, Blue Ribbon and the 3K screen program through Inaphaea as we aim to deliver significant value accretion throughout 2026.”

Share Capital Update

Following First Admission, ValiRx’s enlarged issued share capital will comprise 486.65M ordinary shares of 0.1 pence each, with no treasury shares held. The company plans to convene a General Meeting to approve the issuance of the new shares, warrants, and related instruments.

Share Performance

VAL’s shares trading at GBX 0.28 per share on 30 October 2025, Down by 42.11% from its previous close of GBX 0.048.